
Activist Investor Elliott Turns up the Heat on GSK
Emma Walmsley, CEO of GlaxoSmithKline, under attack from activist investor Elliott Management, has received the backing of the company’s board, which said it “strongly believes” she is the “right leader” for the UK’s largest drugmaker after the planned spinoff of its consumer health business and “fully supports” the steps she’s taking to improve performance.”







































